Launch Date
10/04/2023 at 4:00 am EST
Credit Amount
1.0
Credit Expires
10/04/2024
The diagnosis of narcolepsy can lead to the following question for providers—now what? Between available treatment options, individual patient circumstances, and cardiovascular (CV) comorbidities, it is critical that health care professionals (HCPs) consider and incorporate these factors in treatment decision-making. In determining treatment for narcolepsy, the patient’s quality of life (QoL), lifestyle, and social determinants of health (SDoH) should remain at the core of treatment considerations. Due to the sodium composition among current treatments for narcolepsy, HCPs should select a treatment plan that is appropriate based upon individual CV factors. Alongside CV comorbidities, dosing and titration strategies should also be considered during treatment decision-making.
The final episode of this CMEO BriefCase series on narcolepsy focuses on weighing different treatment plans and optimization, considering CV comorbidities, and individualizing care based on the patient’s QoL, lifestyle, and SDoH. This activity features a panel of experts in the field as well as capturing the patient perspective from the founder of Project Sleep, Julie Flygare.
Initiate or, where appropriate, switch treatment plans for narcolepsy that consider CV comorbidities, dosing, and titration strategies.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Sleep specialists, primary care practitioners, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Zee reports the following financial relationships:
Advisory Board: Eisai Inc.; Harmony Biosciences; and Jazz Pharmaceuticals, Inc.
Consultant: Eisai Inc.; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Grants: Sleep Number Corporation and Vanda Pharmaceuticals
Dr. Karl Doghramji reports the following financial relationships:
Consultant: Axsome; Biogen; Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals Ltd; Imbrium Therapeutics; Inspire Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; and Purdue Pharma
Research Support: Inspire Pharmaceuticals, Inc.
Stock Shareholder (directly purchased): Merck & Co., Inc.
Dr. Paul Doghramji reports the following financial relationships:
Advisory Board: Bayer; Eisai Inc.; and Idorsia Pharmaceuticals Ltd
Speakers Bureau: AbbVie Inc.; Eisai Inc.; Idorsia Pharmaceuticals Ltd; and Merck & Co., Inc.
Stock Shareholder (directly purchased): CVS Health Corporation and Pfizer Inc.
Ms. Flygare reports the following financial relationships:
Consultant: Alkermes
Speakers Bureau: Harmony Biosciences (paid to give one presentation on patient perspective)
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
BC-102-100423-43